Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 938,258
  • Shares Outstanding, K 180,088
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,490 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.82

Options Overview Details

View History
  • Implied Volatility 389.62% (+33.81%)
  • Historical Volatility 44.58%
  • IV Percentile 87%
  • IV Rank 38.03%
  • IV High 895.68% on 01/21/26
  • IV Low 79.11% on 08/13/25
  • Expected Move (DTE 18) 2.34 (45.21%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 131
  • Volume Avg (30-Day) 2,768
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 34,384
  • Open Int (30-Day) 50,529
  • Expected Range 2.83 to 7.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.10
  • Number of Estimates 8
  • High Estimate -0.09
  • Low Estimate -0.15
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.87 +6.06%
on 03/24/26
5.88 -12.09%
on 03/04/26
-0.49 (-8.58%)
since 02/27/26
3-Month
4.79 +7.83%
on 01/06/26
6.88 -24.93%
on 02/03/26
-0.01 (-0.10%)
since 12/26/25
52-Week
1.33 +288.35%
on 04/01/25
6.88 -24.93%
on 02/03/26
+3.17 (+159.55%)
since 03/28/25

Most Recent Stories

More News
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached...

CMPX : 5.17 (-0.77%)
Compass Therapeutics Provides Corporate Update

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)...

CMPX : 5.17 (-0.77%)
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 5.17 (-0.77%)
Compass Therapeutics Announces Key Leadership Appointments

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 5.17 (-0.77%)
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 5.17 (-0.77%)
Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 5.17 (-0.77%)
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the...

CMPX : 5.17 (-0.77%)
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed...

CMPX : 5.17 (-0.77%)
Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.17 (-0.77%)
Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.17 (-0.77%)

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 5.56
2nd Resistance Point 5.46
1st Resistance Point 5.34
Last Price 5.17
1st Support Level 5.12
2nd Support Level 5.02
3rd Support Level 4.90

See More

52-Week High 6.88
Last Price 5.17
Fibonacci 61.8% 4.76
Fibonacci 50% 4.11
Fibonacci 38.2% 3.45
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.